title: Incidence rate of satellite tumors in renal cell carcinoma.
abstract: BACKGROUND
  Nephron-sparing surgery for incidentally detected small renal tumors has been performed. The main objection to such surgery concerns the incidence rate of satellite renal tumors. In this study, the authors analyzed the rate of incidence and proliferative potential of satellite renal tumors.
  
  
  METHODS
  The tumors of 124 renal cell carcinoma patients with a clinically identified unilateral and single tumor measuring </=90 mm who were examined between November 1991 and May 1997 were analyzed prospectively. The authors determined whether these specimens obtained by radical nephrectomy had satellite tumors, and whether the satellite tumors were reactive with a monoclonal antibody (MoAb), MIB-1, to assess their proliferative potential.
  
  
  RESULTS
  Satellite renal cell carcinomas were detected in 8 of the 124 patients (6.5%). None of the pathologic variables examined (tumor grade, tumor stage, main tumor size, cell pattern, and vascular invasion) were found to be predictive of the presence of satellite tumors. Of these eight tumors, two main tumor specimens and three satellite tumor specimens reacted with the MIB-1 MoAb. The reactivity of MIB-1 correlated with the tumor grade. The satellite tumors were observed to have a proliferative potential compared with the main tumors. Among 86 kidney specimens from patients with urothelial tumors after total nephroureterectomy, 2 (2.3%) contained small renal cell carcinoma but did not show positive staining with the MoAb MIB-1.
  
  
  CONCLUSIONS
  The incidence rate of satellite tumors among 124 renal cell carcinoma patients was 6.5% and the presence of satellite tumors was not predictable. Some of these satellite tumors showed positive staining with the MIB-1 MoAb, but small renal tumors detected in kidney specimens with urothelial tumors did not.
authors.affiliation: Department of Urology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kinouchi
authors.forename: M
authors.initials: M
authors.lastname: Mano
authors.forename: S
authors.initials: S
authors.lastname: Saiki
authors.forename: N
authors.initials: N
authors.lastname: Meguro
authors.forename: O
authors.initials: O
authors.lastname: Maeda
authors.forename: M
authors.initials: M
authors.lastname: Kuroda
authors.forename: M
authors.initials: M
authors.lastname: Usami
authors.forename: T
authors.initials: T
authors.lastname: Kotake
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000276:immunology / Q000473:pathology* / Q000601:surgery; D009392:Nephrectomy; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D000911:Antibodies, Monoclonal